Summary & Overview
CPT 81520: mRNA 58-Gene Breast Cancer Recurrence Score Test
CPT code 81520 represents a high-complexity molecular diagnostic test: mRNA gene expression profiling of 58 genes using hybrid capture, with an algorithmic analysis that produces a breast cancer recurrence score. Nationally, this code captures services used to guide prognostic assessment and therapeutic decision-making for breast cancer patients, where genomic test results inform recurrence risk estimation and potential treatment pathways. Its use reflects the growing role of genomic assays in oncology care and reimbursement policy discussions.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose of the test, typical laboratory settings where the test is performed, and the payer landscape addressed. The publication outlines benchmarks relevant to coverage and utilization, summarizes recent policy and coding guidance affecting molecular diagnostic claims, and provides clinical context on how a recurrence score derived from gene expression profiling is used in breast cancer management.
The content is intended for national audiences including payers, laboratory managers, coding and billing professionals, and oncology clinicians seeking a clear summary of CPT code 81520 and its implications for service coding and policy.
Billing Code Overview
CPT code 81520 describes laboratory testing that performs mRNA gene expression profiling for 58 genes using hybrid capture and applies an algorithmic analysis that integrates patient data with the laboratory results to produce a breast cancer recurrence score. The service type is molecular pathology / genomic diagnostic testing, focused on gene expression profiling. The typical site of service is a clinical molecular diagnostics laboratory or other specialized laboratory setting where high-complexity molecular testing is performed.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 52-year-old woman with newly diagnosed, early-stage, hormone receptor–positive, HER2-negative invasive breast carcinoma undergoes breast-conserving surgery. Final pathology reports a tumor size of 2.1 cm, grade II, with 0–1 positive sentinel lymph node(s). The treating medical oncologist orders a genomic assay to inform adjuvant systemic therapy decisions. A tissue specimen (formalin-fixed paraffin-embedded tumor block) is sent to a molecular diagnostics laboratory. In the lab, a molecular technologist extracts RNA, performs hybrid capture-based mRNA gene expression profiling of a 58-gene panel, and the laboratory information system combines the technical assay results with the patient’s clinicopathologic data to generate an algorithmic breast cancer recurrence score. The laboratory issues a report used by the oncologist to guide recommendations about chemotherapy versus endocrine therapy. Typical site of service is a CLIA-certified reference molecular pathology laboratory or hospital-based molecular diagnostic laboratory; specimens are collected in the hospital, outpatient surgical center, or physician office and shipped to the reference lab.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when only the professional/interpretive component of a test is billed by a physician or pathologist separate from the technical component. |